Biotech Most Volatile: Neuralstem (NYSEMKT:CUR), Aegerion Pharmaceuticals (NASDAQ:AEGR), Galena Biopharma Inc (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN)



Neuralstem, Inc. (NYSEMKT:CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats transplanted with Neuralstem Inc. (NYSEMKT:CUR)’s NSI-566 stem cells in the brain experienced functional improvements. Neuralstem, Inc. (NYSEMKT:CUR) stock performance was 3.74% in last session and finished the day at $3.88. Traded volume was 2.54million shares in the last session and the average volume of the stock remained 1.14million shares. The beta of the stock remained 1.37. Neuralstem, Inc. (NYSEMKT:CUR) insider ownership is 2.20%.

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) marking the third consecutive day the stock has decreased. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) rose 2.79 percent to $44.87 Friday on volume of 2.41million shares. The intra-day range of the stock was $40.50 to $45.98. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has a market capitalization of $1.32billion.

Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. (NASDAQ:GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the “Class Period”). Galena Biopharma Inc (NASDAQ:GALE)’s stock on Mar 28, 2014 reported a decrease of -6.29% to the closing price of $2.22. Its fifty two weeks range is $1.65-$7.77. The total market capitalization recorded $261.69million. The overall volume in the last trading session was 5.03million shares. In its share capital, GALE has 106.69million outstanding shares.

Drug company Geron Corporation (NASDAQ:GERN) is facing a lawsuit brought against it by an investor who claims the company misled shareholders on various aspects of its business, more so about the prospects of its products. The shareholder filed a lawsuit at the U.S. District Court in Northern District California, citing that the company issued misleading and perhaps false statements which violated securities laws. On Friday, shares of Geron Corporation (NASDAQ:GERN) dropped -1.46% to close the day at $2.02. Company return on investment (ROI) is -65.10% and its monthly performance is recorded as -60.08%. Geron Corporation (NASDAQ:GERN) quarterly revenue growth is -60.39%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone